ag真人网址 - J9九游会(China)官网
知识百科
关于ag真人
ag真人简介
管理团队
董事会
联系ag真人
科学与产品管线
产品管线
出版物
研发平台
患者中心
合作伙伴
商业拓展
现有合作
ag真人新闻
ag真人新闻
媒体关注
加入ag真人
职业发展
职业机会
投资者关系
EN
EN
关于ag真人
ag真人简介
管理团队
董事会
科学顾问委员会
联系ag真人
科学与产品管线
研发平台
产品管线
出版物
患者中心
合作伙伴
商业拓展
现有合作
ag真人新闻
ag真人新闻
媒体关注
加入ag真人
职业发展
职业机会
投资者关系
差异化、创新性的产品管线
产品管线
AN2025 (buparlisib)
AN0025 (palupiprant)
AN4005
AN8025
AN1025
AN9025
出版物
研发平台
AN2025
22
2023-10
ESMO Poster
Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN
06
2022-12
SABCS Poster
A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/static breast cancer (REO 026-1)
16
2022-02
Frontiers in Immunology
Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity
14
2021-04
AACR Poster
AN3025: an immune-stimulatory anti-human TNFR2 antibody with strong anti-tumor activity
17
2020-06
Journal for ImmunoTherapy of Cancer
First-in- human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
27
2019-09
ESMO Poster
A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer
18
2019-07
JSMO Poster
A novel CSF1R/c-kit dual antagonist eliminates tumor associated macrophage without elevating intratumoral MDSC level
15
2019-03
ICHNO Poster
Buparlisib(AN2025), a potential treatment option for anti PD 1 non responding tumors
28
2018-02
Clinical Cancer Research
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1
13
2017-10
Breast Cancer Res Treat
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with static breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
25
2017-01
Lancet Oncol
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or static squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial